HomeCompareGGTHF vs ABBV

GGTHF vs ABBV: Dividend Comparison 2026

GGTHF yields 4140.79% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GGTHF wins by $10018711496271.80M in total portfolio value
10 years
GGTHF
GGTHF
● Live price
4140.79%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10018711496271.90M
Annual income
$9,564,341,159,618,468,000.00
Full GGTHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GGTHF vs ABBV

📍 GGTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGGTHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GGTHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GGTHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GGTHF
Annual income on $10K today (after 15% tax)
$351,966.87/yr
After 10yr DRIP, annual income (after tax)
$8,129,689,985,675,697,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GGTHF beats the other by $8,129,689,985,675,676,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GGTHF + ABBV for your $10,000?

GGTHF: 50%ABBV: 50%
100% ABBV50/50100% GGTHF
Portfolio after 10yr
$5009355748136.00M
Annual income
$4,782,170,579,809,246,000.00/yr
Blended yield
95.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GGTHF
No analyst data
Altman Z
-66.5
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GGTHF buys
0
ABBV buys
0
No recent congressional trades found for GGTHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGGTHFABBV
Forward yield4140.79%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$10018711496271.90M$102.3K
Annual income after 10y$9,564,341,159,618,468,000.00$24,771.77
Total dividends collected$9987759787208.71M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GGTHF vs ABBV ($10,000, DRIP)

YearGGTHF PortfolioGGTHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$424,779$414,078.67$11,550$430.00+$413.2KGGTHF
2$16,892,998$16,438,485.13$13,472$627.96+$16.88MGGTHF
3$629,048,550$610,973,041.85$15,906$926.08+$629.03MGGTHF
4$21,935,649,065$21,262,567,116.43$19,071$1,382.55+$21935.63MGGTHF
5$716,415,311,987$692,944,167,487.48$23,302$2,095.81+$716415.29MGGTHF
6$21,917,463,606,071$21,150,899,222,244.91$29,150$3,237.93+$21917463.58MGGTHF
7$628,194,188,737,040$604,742,502,678,543.50$37,536$5,121.41+$628194188.70MGGTHF
8$16,871,247,239,066,280$16,199,079,457,117,650.00$50,079$8,338.38+$16871247239.02MGGTHF
9$424,645,174,442,460,860$406,592,939,896,659,900.00$69,753$14,065.80+$424645174442.39MGGTHF
10$10,018,711,496,271,900,000$9,564,341,159,618,468,000.00$102,337$24,771.77+$10018711496271.80MGGTHF

GGTHF vs ABBV: Complete Analysis 2026

GGTHFStock

Golden Goliath Resources Ltd. engages in the acquisition and exploration of resource properties. The company primarily explores and develops gold and silver properties located in the Red Lake District of Ontario, Canada. It also holds a 100% interest in the San Timoteo property located in the Sierra Madre Occidental Mountains of northwestern Mexico; and the La Cruz property located in the central part of Chihuahua. Golden Goliath Resources Ltd. was incorporated in 1996 and is based in Vancouver, Canada.

Full GGTHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GGTHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GGTHF vs SCHDGGTHF vs JEPIGGTHF vs OGGTHF vs KOGGTHF vs MAINGGTHF vs JNJGGTHF vs MRKGGTHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.